Abivax: Obefazimod Achieves Main Goal in Phase 3 for UC
Abivax announced on Monday positive results from the phase 3 ABTECT maintenance trial evaluating obefazimod in active moderate to severe ulcerative colitis. The two tested doses, 25 mg and 50 mg administered once daily, achieved the primary endpoint of clinical remission at week 44, with adjusted differences versus placebo of 39.3 and 40.3 percentage points, respectively. The release also reports a generally favorable safety profile, while detailing several cases of cancers or precancerous lesions observed in the trial, primarily in the 50 mg group.
At week 44 of the ABTECT trial, obefazimod met the primary evaluation criterion in both dosages studied. The 25 mg dose achieved a clinical remission rate of 50.8%, compared to 10.4% under placebo, representing an adjusted difference of 39.3 percentage points. The 50 mg dose recorded a clinical remission rate of 51.3%, also against 10.4% under placebo, corresponding to an adjusted difference of 40.3 percentage points. In both cases, the differences were statistically significant.
A Global Maintenance Study in Ulcerative Colitis
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The ABTECT maintenance trial is a global phase 3, multicenter, randomized, double-blind, placebo-controlled study. It evaluated the long-term efficacy and safety of obefazimod in adults with active moderate to severe ulcerative colitis. Participants, who responded after the ABTECT-1 and ABTECT-2 induction trials, were re-randomized to receive either 25 mg of obefazimod, 50 mg of obefazimod, or a placebo.
Secondary Endpoints Also Met
Abivax reports that both doses of obefazimod also met all the main secondary endpoints, including endoscopic improvement, endoscopic remission, histologic-endoscopic mucosal improvement, clinical remission without corticosteroids, and sustained clinical remission. For endoscopic improvement, the rates were 54.9% with 25 mg and 64.1% with 50 mg, compared to 12.5% under placebo. For endoscopic remission, the rates reached 41.5% and 47.7%, compared to 9.9% under placebo.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 3T 2025
Guidance from the release
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
